Personalis Inc PSNL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis and Tempus Announce Expanded Collaboration
-
Personalis Reports Second Quarter 2024 Financial Results
-
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
-
Personalis to Announce Second Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $5.22
- Day Range
- $5.17–5.54
- 52-Week Range
- $0.89–7.20
- Bid/Ask
- $5.24 / $5.25
- Market Cap
- $346.82 Mil
- Volume/Avg
- 509,878 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 225
- Website
- https://www.personalis.com
Comparables
Valuation
|
Metric
|
PSNL
|
GRAL
|
TIHE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.47 | 0.17 | — |
Price/Sales | 3.28 | 4.07 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PSNL
|
GRAL
|
TIHE
|
|---|---|---|---|
Quick Ratio | 2.93 | 11.09 | 0.00 |
Current Ratio | 3.31 | 11.55 | 0.00 |
Interest Coverage | −2,072.48 | — | — |
Quick Ratio
PSNL
GRAL
TIHE
Profitability
|
Metric
|
PSNL
|
GRAL
|
TIHE
|
|---|---|---|---|
Return on Assets (Normalized) | −29.69% | −11.72% | — |
Return on Equity (Normalized) | −46.55% | −13.53% | — |
Return on Invested Capital (Normalized) | −37.04% | −13.47% | — |
Return on Assets
PSNL
GRAL
TIHE
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Hpmdrjtjjx | Nsst | $234.7 Bil | |||
| Danaher Corp
DHR
| Dwncthbfg | Lgkwygj | $198.9 Bil | |||
| IQVIA Holdings Inc
IQV
| Wxrkrfby | Mgxjxb | $42.8 Bil | |||
| Agilent Technologies Inc
A
| Ngnyjyfgt | Sxj | $42.5 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Bnsczwmwwp | Zhbf | $42.1 Bil | |||
| Mettler-Toledo International Inc
MTD
| Cnqvlgjqf | Nvrcl | $31.4 Bil | |||
| Icon PLC
ICLR
| Xstzglfrb | Pdsvt | $23.7 Bil | |||
| Waters Corp
WAT
| Xzcdqqywh | Kqm | $21.2 Bil | |||
| Illumina Inc
ILMN
| Tdbprzxz | Rqjfgm | $20.7 Bil | |||
| Labcorp Holdings Inc
LH
| Xcbycrdn | Cwtbsgh | $18.6 Bil |
United States